News

Mayne Pharma Group Limited presentation at Wilsons Rapid Insights conference on 26 May 2022.

Mayne Pharma Group Limited is pleased to announce that its application for a Federal Government Modern Manufacturing Initiative (MMI) Grant has been successful.

Mayne Pharma Group Limited (ASX: MYX) is pleased to announce that Ann Custin has accepted an invitation to join the Board of Mayne Pharma, effective 23 March 2022.

Mayne Pharma’s CEO, Mr Scott Richards said, “At a group level, our underlying results this half have incorporated our significant investment in commercial infrastructure to support the launch of NEXTSTELLIS.

Mayne Pharma Group Limited (ASX: MYX) is pleased to announce it has launched an authorised generic (AG) of one of the largest dermatology products in the United States.

Mayne Pharma Group Limited (ASX: MYX) is pleased to announce that Kathryn MacFarlane, PharmD, has accepted an invitation to join the Board of Mayne Pharma, effective 1 February 2022.

Mayne Pharma Group Limited (ASX: MYX) is pleased to announce it has begun distribution of tacrolimus ointment, 0.1% in the United States

Mayne Pharma Group Limited (ASX: MYX) and Mithra Pharmaceuticals, SA (Euronext Brussels: MITRA) are very pleased to announce the Therapeutic Goods Administration (TGA) has approved the novel combined oral contraceptive NEXTSTELLIS® (14.2 mg of estetrol and 3 mg drospirenone tablets).

Welcome everyone, I'm Frank Condella, the Chair of Mayne Pharma. It is a pleasure to welcome you to Mayne Pharma’s 2021 Annual General Meeting. As we have a quorum present, I am delighted to open the meeting